MedTrace Logo

The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder

NCT06115603 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2025-04-02

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the effects of Cannabigerol (CBG) on indicators of Attention-Deficit/Hyperactivity Disorder (ADHD) in a sample of participants indicating/reporting symptoms associated with ADHD. The main question it aims to answer is: Does CBG reduce ADHD-related indicators relative to placebo? Participants will administer an acute dose of placebo or 80mg CBG and complete outcome measures at 45 minutes and 75 minutes. Daily surveys to monitor safety will be administered for one week following administration.

Conditions

  • Attention-Deficit/Hyperactivity Disorder

Interventions

DRUG

Cannabigerol

1 mL of 80mg Cannabigerol once during experimental session

OTHER

Placebo

1 mL of placebo once during experimental session

Sponsors & Collaborators

  • University of Arkansas, Fayetteville

    lead OTHER

Principal Investigators

  • Ellen W Leen-Feldner, PhD · University of Arkansas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-14
Primary Completion
2025-12-31
Completion
2025-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06115603 on ClinicalTrials.gov